Home Coronavirus Johnson & Johnson Vaccine Might Save the Company

US health care giant Johnson & Johnson, beset by recent scandals over talcum powder and the opioid crisis, is poised for a reputational lift with its pathbreaking coronavirus vaccine.

J & J, which has vowed to sell the vaccine at cost, won approval Thursday from the European Union for its Covid-19 jab after receiving the green light earlier from regulators in the United States, Canada and South Africa.

The J & J inoculation is the first approved by health authorities to require just one shot, the latest breakthrough for an industry that had been on the outs with the general public prior to Covid-19.

“The pharmaceutical industry was once thought of in such high regard in the 1990s but a lot of that admiration has been lost due to drug prices,” said Damien Conover, a health care analyst at Morningstar.

Consumers detect “arrogance” in how pharma giants “push around the drug as the only solution to people’s health issues,” said Daniel Binns, head of Interbrand, a New York-based marketing consultancy.

“They just have this terrible reputation” despite creating “incredible drugs,” Binns added.

J & J has come under fire in its home market in the wake of lawsuits that its talcum powder products cause cancer and over its marketing of prescription painkillers amid the country’s opioid crisis.

But the vaccine offers a shot at “brand redemption,” said Vann Graves, director of the Virginia Commonwealth University’s Brandcenter.

– ‘Halo effect’? –

By any measure, the pharma industry’s vaccine program in response to Covid-19 has met the moment in confronting a global health scourge that has claimed more than 2.6 million lives worldwide.

“Any chance they have now to shine some positive light on their corporate brand makes total sense,” Binns said. “Why wouldn’t you if, for the first time in a long time, people are going ‘Okay, I can see that you do some good things.'”

If anything, J & J, which makes myriad over-the-counter and prescription medicines, as well as shampoos and face creams, is already well-known among the general public.

“We thought we had a responsibility as the world’s largest health care company to step up, much like we did with Ebola a number of years ago,” the company’s chief financial officer, Joseph Wolk, told an investor conference earlier this month.

“Just stabilizing the society, if you will, has a benefit to our business,” Wolk said.

A reopened economy is expected to boost J & J, which has seen sales decline on items tied to non-emergency medical procedures, as well as for sunscreen and other travel items.

But J & J could shift its approach once the pandemic ends, potentially if it develops booster shots to address variants of Covid-19.

“What kind of commercial opportunity is there on the horizon? Probably not in 2021,” Wolk said. “But as we move to 2022, we are looking at it more as a business opportunity.”

However, Conover noted that J & J must “be a little careful” about seeking to profit from the vaccine after accepting public funds during its development.

Wolk has also expressed hope that J & J’s vaccine success could pave the way for improved terms in other negotiations with governments.

“To say that we’ve incorporated any kind of halo effect or think this is going to help us in the next tough negotiation, I’d like to think so, but I think that would be a little bit too optimistic,” he said.

But the success of the vaccine program will likely shift the debate on drug prices. Prior to Covid-19, both major political parties had castigated the industry over runaway prices.

“With the development of Covid-19 vaccines, the policymakers understand the importance of a very vibrant drug industry,” Conover said. “And the changes are going to be more moderate because of that.”

You may also like

logo-white

Your Trusted Source for Capital Markets & Related News

Latest Articles

© 2024 LiveTradingNews.com – For The Traders, By The Traders – All Right Reserved.

The information contained on this website shall not be construed as (i) an offer to purchase or sell, or the solicitation of an offer to purchase or sell, any securities or services, (ii) investment, legal, business or tax advice or an offer to provide such advice, or (iii) a basis for making any investment decision. An offering may only be made upon a qualified investor’s receipt not via this website of formal materials from the Knightsbridge an offering memorandum and subscription documentation (“offering materials”). In the case of any inconsistency between the information on this website and any such offering materials, the offering materials shall control. Securities shall not be offered or sold in any jurisdiction in which such offer or sale would be unlawful unless the requirements of the applicable laws of such jurisdiction have been satisfied. Any decision to invest in securities must be based solely upon the information set forth in the applicable offering materials, which should be read carefully by qualified investors prior to investing. An investment with Knightsbridge is not suitable or desirable for all investors; investors may lose all or a portion of the capital invested. Investors may be required to bear the financial risks of an investment for an indefinite period of time. Qualified investors are urged to consult with their own legal, financial and tax advisors before making any investment. Knightsbridge is a private investment firm that offers investment services to Qualified Investors, Members and Institutions ONLY. Qualified Investors are defined as individuals who have met those Qualifications in the relevant jurisdictions. Members are defined as individuals who have been accepted into the Knightsbridge membership program. Institutions are defined as entities such as banks, pension funds, and hedge funds. If you are not a Qualified Investor, Member or Institution, you are not eligible to invest with Knightsbridge. All investments involve risk, and there is no guarantee of profit. You may lose some or all of your investment. Past performance is not indicative of future results. Knightsbridge is not a registered investment advisor, and this disclaimer should not be construed as investment advice. Please consult with a qualified financial advisor before making any investment decisions. By accessing this website, you agree to the terms of this disclaimer. Thank you for your interest in Knightsbridge.
CLOSE